Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.76 |
| ▸ | CHKA | P35790 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRND | Q07001 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161236 | 1.00 | CHRNB2 (0.76) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL30241910 | 0.98 | CHRNB2 (0.73) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL30241909 | 0.98 | CHRNB2 (0.73) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL1462348 | 0.98 | CHRNB2 (0.73) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL11544331 | 0.96 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL6352765 | 0.88 | CHRNB2 (0.61) | CHRNB2CHRNA4 | |
| SCHEMBL5655866 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL6350076 | 0.86 | CHRNB2 (0.91) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL5655570 | 0.84 | CHRNB2 (0.61) | CHRNB2CHRNA4CHKA | |
| SCHEMBL3061045 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083630-A1 | HETEROAROMATIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-24 | — | — | WO | claimed |
| EP-4061813-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2022-09-28 | — | — | EP | claimed |
| WO-2025083630-A1 | HETEROAROMATIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-24 | — | — | WO | disclosed |
| CN-119120406-A | Imine reductase mutant and application thereof | 仙居两山生物科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | CHRNB2 4860/4885CHRNA4 4873/4885CHKA 3001/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | CHRNB2 2854/4885CHRNA4 2804/4885CHKA 3593/4885 |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | CHRNB2 696/4885CHRNA4 1015/4885CHKA 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.